Does Rallies show 13F holders for ATOS?

Yes. Rallies tracks hedge fund and 13F ownership data for ATOS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ATOS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATOS. It does not provide personalized investment advice.

ATOS (Atossa Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Atossa Therapeutics, Inc. Common Stock (ATOS) is a publicly traded Healthcare sector company. As of May 20, 2026, ATOS trades at $5.00 with a market cap of $41.16M and a P/E ratio of -1.20. ATOS moved +2.00% today. Year to date, ATOS is -47.72%; over the trailing twelve months it is -65.75%. Its 52-week range spans $3.76 to $24.90. Analyst consensus is strong buy with an average price target of $23.00. Rallies surfaces ATOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ATOS stock?

Hedge funds tracked by Rallies that own ATOS include Exoduspoint Capital. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atossa Therapeutics, Inc. Common Stock.

ATOS Key Metrics

Key financial metrics for ATOS
Metric	Value
Price	$5.00
Market Cap	$41.16M
P/E Ratio	-1.20
EPS	$-4.04
Dividend Yield	0.00%
52-Week High	$24.90
52-Week Low	$3.76
Volume	36.52K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-34.77M
Gross Margin	0.00%

Top Hedge Funds Holding ATOS

Exoduspoint Capital holds 13.52K shares of ATOS, changed -47.94% as of Jun 30, 2025.

Latest ATOS News

Atossa’s Manuscript on (Z)-Endoxifen Utrophin Modulation Accepted for Publication — May 20, 2026
Atossa Sees Q1 Operating Costs Climb 35% to $9.9M as FDA Awards Orphan, RPD Status for (Z)-Endoxifen — May 8, 2026
Atossa Wins FDA Rare Pediatric Designation, PRV Worth $100–$205M — May 4, 2026
Atossa Therapeutics’ Expenses Jump 35% to $37.1M, Gains FDA Rare Disease Designations — Mar 25, 2026
Atossa Hires Two Clinical Directors for Breast Cancer and Rare Disease Programs — Mar 19, 2026

Recent ATOS Insider Trades

QUAY STEVEN C bought 11.24K (~$9.89K) on May 21, 2025.
Remmel H. Lawrence bought 10.00K (~$7.00K) on Mar 26, 2025.
Finn Jonathan bought 25.00K (~$44.25K) on Apr 10, 2024.

ATOS Analyst Consensus

3 analysts cover ATOS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.00.

Common questions about ATOS

Who owns ATOS stock?: Hedge funds tracked by Rallies that own ATOS include Exoduspoint Capital. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atossa Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ATOS?: Yes. Rallies tracks hedge fund and 13F ownership data for ATOS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ATOS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATOS. It does not provide personalized investment advice.